Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This novel dual incretin mechanism targets both GIP and GLP-1 receptors simultaneously, representing a significant advancement in metabolic peptide research. Studies have demonstrated its potential effects on glycemic control, body weight regulation, and metabolic parameters. The unique dual-receptor targeting mechanism provides researchers with valuable insights into incretin biology and metabolic pathway modulation.